Welcome to our dedicated page for RESPIRERX PHARMA news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on RESPIRERX PHARMA stock.
RESPIRERX PHARMA INC (RSPI) is a pharmaceutical company focused on developing innovative treatments for various respiratory disorders and neurological conditions. The company's core business revolves around the research and development of therapeutic solutions that target specific neurotransmitter pathways to address unmet medical needs.
RESPIRERX PHARMA INC has recently made significant strides in advancing its lead product candidates, including ResolutionRx, a novel pharmaceutical cannabinoid being developed to treat respiratory conditions, and EndeavourRx, a cutting-edge neuromodulator designed to address neurological disorders. The company's financial condition remains robust, supported by strategic partnerships and a pipeline of promising products in various stages of development.
RespireRx Pharmaceuticals (OTCQ:RSPI) announced that Dr. Arnold Lippa, Executive Chairman and Chief Scientific Officer, will speak at the 5th International Cannabinoid-Derived Pharmaceuticals Summit from September 6-8, 2022, in Boston, MA. He will discuss the company's innovative lipid nanoparticle formulation technology aimed at repurposing dronabinol for obstructive sleep apnea (OSA) and other disorders. With over 29 million affected by OSA in the U.S., RespireRx is advancing clinical trials, including two Phase 2 studies showing promising results and plans for a Phase 3 study pending FDA discussions.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced that Dr. Arnold Lippa, Chief Scientific Officer, spoke at the 2022 GRI Virtual Conference on April 23. He presented data on the potential use of AMPAkines for treating GRI disorders, which include cognitive deficits and treatment-resistant seizures. Dr. Lippa highlighted positive results of AMPAkines in animal models simulating GRI disorders. The company's EndeavourRx unit is focused on developing these low-impact AMPAkines. RespireRx aims to collaborate with CureGRIN Foundation to advance treatments for GRI disorders.
RespireRx Pharmaceuticals (OTCQB:RSPI) announced the publication of a manuscript highlighting potential novel treatments for tinnitus, a disorder affecting 10-15% of the global population. The review by RespireRx scientists suggests that loss of GABA neurotransmission may contribute to tinnitus, with older GABAkines showing some symptom improvement despite side effects. The manuscript aims to energize the search for effective treatments. Additionally, RespireRx is developing KRM-II-81, a GABAkine, which may offer a game-changing solution for tinnitus patients.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the filing of a provisional patent application for a novel lipid-based formulation technology (LFT) to enhance the solubility and bioavailability of poorly soluble drugs, with a focus on cannabinoids. Their ResolutionRx unit is advancing dronabinol formulations for obstructive sleep apnea (OSA), having completed two Phase 2 trials showing significant symptom reduction. The company plans further testing pending financing. Improved formulations aim to expand market opportunities for dronabinol, including potential treatments beyond current approvals.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the publication of a manuscript on D5-KRM-II-81, detailing its pharmacology. The study, led by Dr. Jeffrey M. Witkin, highlights the compound's ability to prevent seizures and its potential in treating pharmacoresistant epilepsy and pain. The findings support D5-KRM-II-81 as a promising orally-bioavailable option alongside KRM-II-81, which targets GABAA receptors. This advancement is crucial for addressing significant unmet medical needs in epilepsy and chronic pain treatment.
RespireRx Pharmaceuticals (OTCQ:RSPI) reviews its progress over the past year and outlines future plans. The company aims to unlock value through restructuring and two key platforms: pharmaceutical cannabinoids and neuromodulators. Recent achievements include successful trials with dronabinol for obstructive sleep apnea and advancements in AMPAkines and GABAkines for spinal cord injury and epilepsy treatments. However, financing challenges persist, particularly with the stock below the $0.02 offering price set for up to $7.5 million. Leadership changes were also noted, with Dr. Arnold Lippa stepping in as Interim CEO.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) has announced the publication of a manuscript detailing the pharmacology of its compound KRM-II-81, marking a significant advancement in developing GABAkines for neurological and psychiatric disorders. The paper describes KRM-II-81's efficacy against pharmacoresistant epilepsy and neuropathic pain, showcasing its low sedation effects and lack of tolerance development. The company's leadership sees potential in KRM-II-81 as a breakthrough treatment, moving towards IND enabling studies to address significant unmet medical needs.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announces participation in two upcoming investor conferences. CFO Jeff Margolis will present live at the Life Sciences Virtual Investor Conference on December 16, 2021, discussing the company’s vision and programs. Concurrently, President and CEO Tim Jones will present a pre-recorded video at the Biotech Showcase from January 17-19, 2022. These platforms offer insights into RespireRx's innovative treatments for psychiatric and neurological disorders, including obstructive sleep apnea and ADHD.
RespireRx Pharmaceuticals (OTCQB: RSPI) has published a pivotal review article on GABAkines, focusing on the development of positive allosteric modulators of GABAA receptors. This article highlights the potential of KRM-II-81, a GABAkine in development, to treat epilepsy and pain with reduced side effects compared to traditional benzodiazepines. KRM-II-81 shows promise in preclinical studies, demonstrating high anti-convulsant and analgesic activities without the risks of tolerance or dependence. The findings strongly support advancements in treatment options for neurological disorders.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of research on KRM-II-81, a novel analgesic, in the book The Neurobiology, Physiology, and Psychology of Pain. This compound selectively potentiates GABAA receptors, showing significant analgesic efficacy without common opioid side effects. KRM-II-81 demonstrated comparable or superior analgesic effects in animal models compared to traditional analgesics, while avoiding tolerance, dependence, and respiratory depression. The company is optimistic about KRM-II-81's potential to address pain management amidst the opioid crisis.
FAQ
What is the current stock price of RESPIRERX PHARMA (RSPI)?
What is the market cap of RESPIRERX PHARMA (RSPI)?
What is the primary focus of RESPIRERX PHARMA INC?
What are some of the lead product candidates of RESPIRERX PHARMA INC?
Where is RESPIRERX PHARMA INC headquartered?
How can I contact Jeff Margolis of RESPIRERX PHARMA INC?
What is the website of RESPIRERX PHARMA INC?
